Literature DB >> 21317622

Therapeutic cancer vaccines: the latest advancement in targeted therapy.

Marijo Bilusic1, Ravi A Madan.   

Abstract

Therapeutic cancer vaccines represent an emerging therapeutic modality that may play a more prominent role in cancer treatment in the future. Therapeutic cancer vaccines are designed to generate a targeted, immune-mediated antitumor response. There are 2 main types of therapeutic vaccines: patient-specific (generated either from a patient's own cells or tumor) and patient- nonspecific, where a peptide- or vector-based vaccine induces an immune response in vivo against specific tumor-associated antigens. Studies are currently underway to investigate methods to enhance vaccine strategies, including combinations with standard anticancer therapies or immune-modulating agents. Cancer vaccines are usually well tolerated, with minimal toxicity compared with chemotherapy. This review summarizes selected therapeutic cancer vaccines in late clinical development.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 21317622      PMCID： PMC3601372          DOI： 10.1097/MJT.0b013e3182068cdb

Source DB:  PubMed          Journal:  Am J Ther        ISSN： 1075-2765            Impact factor:   2.688


  57 in total

1.  Multiple costimulatory modalities enhance CTL avidity.

Authors:  James W Hodge; Mala Chakraborty; Chie Kudo-Saito; Charlie T Garnett; Jeffrey Schlom
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

2.  Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells.

Authors:  C Czerkinsky; G Andersson; H P Ekre; L A Nilsson; L Klareskog; O Ouchterlony
Journal:  J Immunol Methods       Date:  1988-05-25       Impact factor: 2.303

Review 3.  Prognostic factors in low-grade non-Hodgkin lymphomas.

Authors:  Massimo Federico; Stefano Molica; Monica Bellei; Stefano Luminari
Journal:  Curr Hematol Malig Rep       Date:  2009-10       Impact factor: 3.952

4.  Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation.

Authors:  Edward Y Woo; Heidi Yeh; Christina S Chu; Katia Schlienger; Richard G Carroll; James L Riley; Larry R Kaiser; Carl H June
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

5.  Automation of the ELISpot assay for high-throughput detection of antigen-specific T-cell responses.

Authors:  Coral-Ann M Almeida; Steven G Roberts; Rebecca Laird; Elizabeth McKinnon; Imran Ahmed; Katja Pfafferott; Joanne Turley; Niamh M Keane; Andrew Lucas; Ben Rushton; Abha Chopra; Simon Mallal; Mina John
Journal:  J Immunol Methods       Date:  2009-03-10       Impact factor: 2.303

6.  Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine.

Authors:  Benedetto Farsaci; Helen Sabzevari; Jack P Higgins; Maria Giovanna Di Bari; Shinji Takai; Jeffrey Schlom; James W Hodge
Journal:  Int J Cancer       Date:  2010-10-01       Impact factor: 7.396

7.  Clinical safety of a viral vector based prostate cancer vaccine strategy.

Authors:  Philip M Arlen; Lisa Skarupa; Mary Pazdur; Mahesh Seetharam; Kwong Y Tsang; Douglas W Grosenbach; Jarett Feldman; Diane J Poole; Mary Litzinger; Seth M Steinberg; Elizabeth Jones; Clara Chen; Jennifer Marte; Howard Parnes; John Wright; William Dahut; Jeffrey Schlom; James L Gulley
Journal:  J Urol       Date:  2007-08-16       Impact factor: 7.450

8.  Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells.

Authors:  J J Mulé; S L Schwarz; A B Roberts; M B Sporn; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

9.  MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy.

Authors:  Preeta Tyagi; Beloo Mirakhur
Journal:  Clin Lung Cancer       Date:  2009-09       Impact factor: 4.785

Review 10.  Current developments in cancer vaccines and cellular immunotherapy.

Authors:  Antoni Ribas; Lisa H Butterfield; John A Glaspy; James S Economou
Journal:  J Clin Oncol       Date:  2003-06-15       Impact factor: 44.544
View more
  11 in total

Review 1.  Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.

Authors:  Helen Y Wang; Rong-Fu Wang
Journal:  Adv Immunol       Date:  2012       Impact factor: 3.543

2.  Tumor cells endowed with professional antigen-presenting cell functions prime PBLs to generate antitumor CTLs.

Authors:  Chiara Chiozzini; Eleonora Olivetta; Massimo Sanchez; Claudia Arenaccio; Flavia Ferrantelli; Patrizia Leone; Maurizio Federico
Journal:  J Mol Med (Berl)       Date:  2019-06-03       Impact factor: 4.599

Review 3.  Immune targets and neoantigens for cancer immunotherapy and precision medicine.

Authors:  Rong-Fu Wang; Helen Y Wang
Journal:  Cell Res       Date:  2016-12-27       Impact factor: 25.617

4.  Optimized Liquid and Gas Phase Fractionation Increases HLA-Peptidome Coverage for Primary Cell and Tissue Samples.

Authors:  Susan Klaeger; Annie Apffel; Karl R Clauser; Siranush Sarkizova; Giacomo Oliveira; Suzanna Rachimi; Phuong M Le; Anna Tarren; Vipheaviny Chea; Jennifer G Abelin; David A Braun; Patrick A Ott; Hasmik Keshishian; Nir Hacohen; Derin B Keskin; Catherine J Wu; Steven A Carr
Journal:  Mol Cell Proteomics       Date:  2021-08-12       Impact factor: 7.381

5.  Design of a new multi-epitope peptide vaccine for non-small cell Lung cancer via vaccinology methods: an in silico study.

Authors:  Fatemeh Heidary; Mehdi Tourani; Fatemeh Hejazi-Amiri; Seyyed Hossein Khatami; Navid Jamali; Mortaza Taheri-Anganeh
Journal:  Mol Biol Res Commun       Date:  2022-03

Review 6.  IgE-based immunotherapy of cancer: challenges and chances.

Authors:  J Singer; E Jensen-Jarolim
Journal:  Allergy       Date:  2013-10-14       Impact factor: 13.146

7.  Identifying the Most Effective Hydatid Cyst Fluid Fraction for Anticancer Vaccination of 4T1 Breast Tumor-Bearing Mice.

Authors:  Shima Daneshpour; Shahla Rostamirad; Amirhosein Kefayat; MohammadReza Mofid; Ashkan Safavi; Hossein Yousofi Darani
Journal:  Int J Prev Med       Date:  2019-08-12

8.  Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008.

Authors:  Liangjian Lu; Haixi Yan; Vijay Shyam-Sundar; Tobias Janowitz
Journal:  Drug Des Devel Ther       Date:  2014-09-27       Impact factor: 4.162

Review 9.  New Cancer Therapies: Implications for the Perioperative Period.

Authors:  Tayab Andrabi; Katy E French; Muzaffar H Qazilbash
Journal:  Curr Anesthesiol Rep       Date:  2018-12-06

Review 10.  Mechanistic diversity in MHC class I antigen recognition.

Authors:  Camila R R Barbosa; Justin Barton; Adrian J Shepherd; Michele Mishto
Journal:  Biochem J       Date:  2021-12-22       Impact factor: 3.857
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.